Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology

Abzu, an applied research startup who has developed a pioneering explainable artificial intelligence (xAI), and Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, are partnering to design nucleic acid-based medicines. Abzu will collaborate exclusively with Contera Pharma on two undisclosed targets within rare neurological diseases. According to recent research in European […]

Contera Pharma elected new executive management team

Contera Pharma, a subsidiary of Bukwang, announced that it elected Dr. Thomas Sager as CEO while further expanding the executive management team to include representatives for Business Development and R&D Chief Executive Officer; Thomas Sager, PhD. Chief Business Officer; Anders Brandt Elvang, PhD. Chief Science Officer; Kenneth Vielsted Christensen, PhD. Thomas Sager, received his PhD […]

Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019. Contera, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The […]

Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND

Contera Pharma is preparing for public offering in KOSDAQ Bukwang has recently received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase 2 clinical study of JM-010. JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in […]